Salarius Pharmaceuticals, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis

Kronos Bio, Inc. implemented a restructuring plan in November that resulted in a 19% workforce reduction but extended its cash runway into 2026 and the company unveiled further cost cuts on 7 March t

Having an approved and marketed drug is not enough to keep a biopharmaceutical company alive in the current financing environment in which stock prices are down and public offerings are not viable fun

Merck & Co., Inc. is well aware that it needs to begin planning for its post-Keytruda future, with the blockbuster anti-PD-1 agent slated to lose patent protection in 2028, but with its plans for a l